As the top selling five biological products face patent expiration in the US, more companies are poised to move into biosimilars. With the regulatory pathway now established, there is no doubt that the competition to commercialise will be tight. Which strategies have proven the most effective for the EU market? And what impact might they have in the US market? Learn more.
Torrent Pharmaceuticals and Elder Pharmaceuticals announced Friday that the companies reached a definitive agreement under which Torrent will acquire latter's branded domestic formulations business in... Read More >>